查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239517

視神經病變治療市場：按治療類型、適應症、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Optic Nerve Disorders Treatment Market By Treatment Type, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 257 Pages | 商品交期: 2-3個工作天內

價格

2021年全球視神經病變治療市場規模將達到33.7246億美元，預計2031年將達到52.4782億美元，2022-2031年復合年增長率為4.5%。

眼睛的視神經是第二腦神經，有助於將視覺的感覺資訊傳遞到大腦。 這種神經在胎兒發育過程中從前腦中的視神經小泡發育而來。 如果視神經或其通往大腦的通路受損，視力就會受損。

不同類型的視神經病變，例如青光眼、視神經萎縮和視神經炎，在世界各地普遍存在。 許多這些疾病都是對症治療的。 治療不會改善視力，但可以防止因殘疾而導致的視力進一步喪失。

由於患有眼病的老年人口不斷增加、創新技術的引入、醫療保健支出的增加以及政府支持的增加，預計在預測期內視神經病變治療市場將出現顯著的市場增長。 此外，公司增加研發投資、強大的管道候選人的存在以及醫療基礎設施開發支出的增加將進一步推動市場增長。 然而，熟練專業人員的短缺預計會阻礙市場增長。 另一方面，公共機構和私營公司的醫療保健投資激增，預計將為視神經病變治療市場帶來重大增長機會。

視神經病變治療市場按治療類型、適應症、分銷渠道和地區劃分。 按治療類型，市場分為類固醇治療、免疫調節劑治療和其他治療類型。 根據適應症，市場分為視神經炎、青光眼、視神經萎縮等。 按銷售渠道劃分，它分為醫院藥房、藥店、零售藥店和在線供應商。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資領域
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅很大
    • 新進入者的威脅很大
    • 中等強度的競爭
  • 市場動態
    • 促進因素
      • 視神經病變患病率增加
      • 不斷增長的老年人口
      • 技術進步的增加
    • 抑制因素
      • 缺乏熟練的專業人員
    • 機會
      • 新興國家/地區的增長潛力
  • 分析 COVID-19 對市場的影響

第 4 章視神經治療市場：按治療類型分類

  • 概覽
    • 市場規模和預測
  • 類固醇療法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 免疫調節療法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章視神經病變治療市場：按適應症分類

  • 概覽
    • 市場規模和預測
  • 青光眼
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 視神經炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章視神經病變治療市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章視神經病變治療市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 按治療類型劃分的市場規模和預測
    • 市場規模和預測：按適應症
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 神田
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 按治療類型劃分的市場規模和預測
    • 市場規模和預測：按適應症
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 按治療類型劃分的市場規模和預測
    • 市場規模和預測：按適應症
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 按治療類型劃分的市場規模和預測
    • 市場規模和預測：按適應症
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型劃分的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測
      • 其他拉丁美洲/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 按治療類型分類的市場規模和預測
      • 市場規模和預測：按適應症
      • 按分銷渠道劃分的市場規模和預測

第 8 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第 9 章公司簡介

  • Santen Pharmaceutical Co., Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • mallinckrodt pharmaceuticals
  • Merck & Co., Inc.
  • .Aerie Pharmaceuticals, Inc.
  • Cipla Ltd
Product Code: A14042

The global optic nerve disorder treatment market accounted for $3,372.46 million in 2021, and is expected to reach $5,247.82 million by 2031, registering a CAGR of 4.5% from 2022 to 2031.

The optic nerve of the eye is the second cranial nerve, which helps transmit sensory information to the brain for vision. This nerve develops from optic vesicle of the forebrain during fetal development. Damage to the optic nerve or its pathways that lead to the brain may result in the loss of vision. 

Different types of optic nerve disorders are prevalent across the globe such as glaucoma, optic nerve atrophy, optic neuritis and others. Most of these disorders are symptomatically treated. The treatments may not improve vision, but they can help to prevent vision loss that may occur further with the disorder.

It is estimated that optic nerve disorder treatment market is expected to experience significant market growth during the forecast period owing to the increasing geriatric population suffering from eye diseases, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure, which further facilitate the growth of the market. However, Dearth of skilled professionals expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the optic nerve disorder treatment market.

The optic nerve disorder treatment market is segmented on the basis of treatment type, indication, distribution channel and region. Depending on treatment type, the market is classified into steroidal therapy, immunomodulators therapy and others treatment type. On the basis of indication, the market is categorized into optic neuritis, glaucoma, optic nerve atrophy and others. By distribution channel, the market is classified into hospital pharmacies, drug stores, retail pharmacies and online providers. 

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global optic nerve disorder treatment market. The key companies profiled in the report include AbbVie Inc., Alcon Inc, Bausch Health Companies, Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Teva pharmaceutical industries ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the optic nerve disorders treatment market analysis from 2021 to 2031 to identify the prevailing optic nerve disorders treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the optic nerve disorders treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global optic nerve disorders treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment Type

  • Steroidal Therapy
  • Immunomodulators therapy
  • Others

By Indication

  • Glaucoma
  • Optic Neuritis
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canda
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Santen Pharmaceutical Co., Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Bausch Health Companies, Inc.
  • Merck & Co., Inc.
  • .Aerie Pharmaceuticals, Inc.
  • Cipla Ltd
  • mallinckrodt pharmaceuticals
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. High threat of substitutes
    • 3.3.4. High threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of optic nerve disorder
      • 3.4.1.2. Growth in geriatric population
      • 3.4.1.3. Increase in technological advancement
    • 3.4.2. Restraints
      • 3.4.2.1. Dearth of skilled professionals
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth potential of emerging economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Steroidal Therapy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Immunomodulators therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Glaucoma
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Optic Neuritis
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Treatment Type
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Treatment Type
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Treatment Type
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Treatment Type
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Treatment Type
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Treatment Type
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Treatment Type
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Treatment Type
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Treatment Type
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Treatment Type
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Treatment Type
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Treatment Type
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Treatment Type
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Treatment Type
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Treatment Type
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Treatment Type
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Treatment Type
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Treatment Type
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Treatment Type
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Treatment Type
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Treatment Type
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Treatment Type
      • 7.5.5.3.3. Market size and forecast, by Indication
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Treatment Type
      • 7.5.5.4.3. Market size and forecast, by Indication
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Santen Pharmaceutical Co., Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. AbbVie Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Novartis AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Pfizer, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Bausch Health Companies, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Teva Pharmaceutical Industries Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. mallinckrodt pharmaceuticals
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Merck & Co., Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. .Aerie Pharmaceuticals, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Cipla Ltd
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. OPTIC NERVE DISORDERS TREATMENT MARKET FOR STEROIDAL THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. OPTIC NERVE DISORDERS TREATMENT MARKET FOR IMMUNOMODULATORS THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. OPTIC NERVE DISORDERS TREATMENT MARKET FOR GLAUCOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OPTIC NEURITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. OPTIC NERVE DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. OPTIC NERVE DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. OPTIC NERVE DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 88. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 89. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 90. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 91. SANTEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
  • TABLE 92. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 93. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 94. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 95. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 96. ABBVIE INC.: KEY STRATERGIES
  • TABLE 97. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 101. NOVARTIS AG: KEY STRATERGIES
  • TABLE 102. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 103. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 104. PFIZER, INC.: PRODUCT SEGMENTS
  • TABLE 105. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 106. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
  • TABLE 107. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
  • TABLE 108. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
  • TABLE 109. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
  • TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 115. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 116. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 117. MALLINCKRODT PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 118. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 119. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 120. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 121. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 122. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 123. .AERIE PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 124. .AERIE PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 125. .AERIE PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 126. .AERIE PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 127. CIPLA LTD: KEY EXECUTIVES
  • TABLE 128. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 129. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 130. CIPLA LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN OPTIC NERVE DISORDERS TREATMENT MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. HIGH THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALOPTIC NERVE DISORDERS TREATMENT MARKET
  • FIGURE 10. OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR STEROIDAL THERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR IMMUNOMODULATORS THERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR GLAUCOMA, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR OPTIC NEURITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OPTIC NERVE DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. OPTIC NERVE DISORDERS TREATMENT MARKET BY REGION, 2021
  • FIGURE 23. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: OPTIC NERVE DISORDERS TREATMENT MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. SANTEN PHARMACEUTICAL CO., LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 54. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 56. PFIZER, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 57. PFIZER, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. BAUSCH HEALTH COMPANIES, INC.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 59. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 64. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. MERCK & CO., INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 69. .AERIE PHARMACEUTICALS, INC.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. .AERIE PHARMACEUTICALS, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 71. .AERIE PHARMACEUTICALS, INC.: REVENUE SHARE BY REGION, 2021 (%)